US-based biomanufacturing firm National Resilience has received around $17.5m in funding to boost the domestic production of key active pharmaceutical ingredients for essential medicines.
The financing is a result of a project agreement with the Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium), a public-private partnership.
Under the terms of the agreement, Resilience has collaborated with Aralez Bio, a biotechnology company developing amino acids using an advanced platform that works based on biocatalysis.
Resilience will use its current Good Manufacturing Process (cGMP) manufacturing capabilities, development expertise, and regulatory experience to enhance critical medicines production.
The funding will enable cGMP manufacturing using Aralez Bio’s advanced technology platform to simplify production processes for active pharmaceutical ingredients, produced within the US.
Also, it will help Resilience become an approved domestic active pharmaceutical ingredient (API) supplier for pharmaceutical manufacturers.
Resilience CEO Rahul Singhvi said: “Securing this manufacturing program for Resilience is a good step forward for the US pharmaceutical manufacturing industry to ensure a more resilient and responsive supply chain.
“With the support from both public and private sectors, we are positioned to enhance and expand domestic production of key starting materials and active pharmaceutical ingredients that often fall into short supply.”
The funding was offered by the Administration for Strategic Preparedness and Response (ASPR), a part of the US Department of Health and Human Services (HHS).
Resilience received the funds through its subsidiary Resilience Government Services.
The company said the collaboration will ensure the availability of life-saving medicines currently in shortage, and support BioMaP-Consortium’s objectives.
Aralez Bio is engaged in the enzymatic synthesis of noncanonical amino acids (ncAAs).
It has developed an enzymatic platform for producing complex amino acids, allowing clients to access amino acids that are used in pharmaceuticals, agriculture, and functional materials.
Aralez Bio CEO Tina Boville said: “Aralez Bio’s proprietary enzyme platform is at the forefront of amino acid chemistry.
“When combined with Resilience’s groundbreaking approach to revolutionizing pharmaceutical manufacturing, this collaboration is strengthening the security of our supply chains.
“We are excited to partner with Resilience and contribute to the renewal of the domestic bio-economy.”
